Luye Pharma's SCLC Treatment Launch in HK and Macao

Photo:Representative Image

Luye Pharma has launched Zepzelca  (lurbinectedin), a new drug for treating SCLC in Hong Kong and Macau.

Lurbinectedin is a new chemical entity and method for treating elderly patients with SCLC. Metastatic disease. Progression during or after platinum-based chemotherapy. Lovenectedin has been approved for release in 16 countries and territories worldwide. Luye Pharma has been granted the rights to develop and commercialize Lovenectedin in mainland China, Hong Kong, and Macau.

Herbert Loong, associate professor in the Department of Clinical Oncology at the Chinese University of Hong Kong and member of the HKCTS, explained: "Unlike traditional chemotherapy, Rubinstein is a selective inhibitor of oncogenic transcription that shows surprising work in SCLC. We believe this will become a new second-line treatment for SCLC and help improve patient survival."

"Rubinectedin is the current standard based on historical data for anticancer activity and safety. better than treatment. It was effective in both platinum-sensitive and platinum-resistant patients with SCLC. "In addition to being used as monotherapy, lubrinectedin can be used in combination with chemotherapy, immunotherapy, and other treatments, thereby increasing the benefit of patients with SCLC," said oncologist expert Antonio Calles, MD at the Gregorio Marañón General Hospital in Madrid, Spain.